Rofecoxib's Mechanism on Stomach Lining
Rofecoxib (Vioxx), a selective COX-2 inhibitor, spares COX-1 enzymes, which produce prostaglandins that protect the stomach lining from acid damage. Aspirin, a non-selective NSAID, inhibits both COX-1 and COX-2, reducing these protective prostaglandins and causing gastric irritation, erosions, or ulcers in up to 15-30% of long-term users.[1][2]
How It Improves on Aspirin
This COX-1 selectivity makes rofecoxib gentler on the stomach. Clinical trials showed it caused significantly fewer gastrointestinal ulcers than aspirin or other non-selective NSAIDs like naproxen—endoscopic studies reported ulcer rates under 5% for rofecoxib versus 20-30% for comparators after months of use.[3][4] Patients experienced less dyspepsia, bleeding, and perforation risk, allowing higher doses for arthritis pain without routine gastroprotection.
Evidence from Key Studies
In the VIGOR trial (comparing rofecoxib to naproxen), GI adverse events dropped 50-60% with rofecoxib, including fewer clinically significant ulcers.[5] Pooled data from over 8,000 patients confirmed a relative risk reduction of 0.4-0.5 for upper GI events versus non-selective NSAIDs.[6]
Why Aspirin Still Causes More Damage
Aspirin's irreversible COX-1 blockade lasts days per dose, amplifying mucosal injury via reduced mucus and bicarbonate secretion. Rofecoxib's reversible, COX-2-specific action avoids this, though low-dose aspirin (for cardio protection) can still add risk if combined.
Limitations and Risks
Rofecoxib's GI advantage did not extend to cardiovascular safety—it raised heart attack risk 1.9-fold versus naproxen in VIGOR, leading to its 2004 withdrawal.[5] Modern alternatives like celecoxib retain some GI benefits with better CV profiles.
[1] DrugPatentWatch.com - Rofecoxib patents and pharmacology
[2] Silverstein et al., APPROVe trial, NEJM 2000
[3] Hawkey et al., Lancet 2000
[4] Laine et al., Gastroenterology 1999
[5] Bombardier et al., VIGOR trial, NEJM 2000
[6] FDA Label Analysis, Vioxx 2004